Today: 29 June 2026
Browse Category

NASDAQ:RNA 26 October 2025 - 27 October 2025

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Novartis will acquire Avidity Biosciences for $72 per share in cash, a deal valuing Avidity at $12 billion and marking a 46% premium over its last close. The transaction, announced Oct. 26, 2025, is expected to close in the first half of 2026. Before closing, Avidity will spin off its early-stage cardiology programs into a new company, with shareholders receiving both cash and SpinCo shares.
27 October 2025
·····
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis will acquire Avidity Biosciences for $12 billion in cash, offering $72 per share—a 46% premium over Avidity’s last close. Avidity’s stock, which ended Friday at $49.15, is expected to jump sharply when markets open. Novartis is targeting Avidity’s RNA therapies for rare muscle diseases, including a lead drug nearing FDA submission. The deal was announced Sunday, Oct. 26, 2025.
26 October 2025
····

Stock Market Today

  • AMD Shares Dip Below Wall Street Targets Amid Semiconductor Sector Selloff
    June 28, 2026, 6:22 PM EDT. Advanced Micro Devices (AMD) shares fell 2.06% to $521.58 on June 26, with trading volume 39% above the 65-day average, reflecting a broader chip sector selloff. AMD's stock is down 5.4% since Monday and trades 7.4% below its 52-week high. The average analyst price target is $502.92, below current levels, while the top estimate stands at $670. Semiconductor peers Nvidia and Intel also declined sharply, pushing the PHLX chip index down 5.3% for the day and 7.9% for the week. UBS analyst Timothy Arcuri maintains a bullish outlook, increasing AMD's target to $670 based on projected CPU server revenue growth through 2030, despite ongoing concerns over AI spending and market inflation pressures in memory prices.

Latest articles

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

29 June 2026
Kroger (NYSE:KR) faces scrutiny after a USDA alert flagged mislabeled Private Selection Honey Dijon chicken in nine states, but with no confirmed adverse reactions and the product already off shelves, the stock closed Friday at $57.73, down 5 cents; any expansion of affected lots or confirmed cases could alter risk for investors.
Go toTop